What Galvus Treats: Main Uses and Benefits

Galvus (vildagliptin) is commonly used to help manage the chronic condition of Type 2 Diabetes Mellitus (T2DM) in adults, and is applied across domains where additional symptomatic support is needed. It is used when dietary and exercise changes alone do not provide adequate control.

Therapeutic Scope

The medication is relevant for easing symptoms related to systemic imbalance, which may be part of symptomatic management in situations where patients experience elevated blood sugar levels. This assists with maintaining functional stability and may support general well-being during symptomatic phases. Its key therapeutic roles include use as a monotherapy in situations where first-line treatments are not suitable or tolerated, or as an add-on therapy to manage symptoms related to heightened physiological activity alongside existing treatments.

This treatment path may assist with easing the overall symptom load related to high blood sugar in situations where existing therapy is insufficient. It is also relevant in conditions where functional stability becomes affected, such as in patient groups who may be intolerant to common first-line treatments, supporting symptomatic management.

---

Quick Fact: Support for Symptom Management
Galvus is considered relevant for use in patient groups seeking blood sugar management that generally does not contribute to weight gain.
It is used in conditions characterized by periods of fluctuating manifestations when targets for blood sugar are not met.

Regulatory References

1. European Medicines Agency (EMA) product information

Galvus (vildagliptin) is authorized for use only in adults (18 years and above) with Type 2 Diabetes Mellitus ( T2DM). The official regulatory profile strictly defines groups who must not use the medicine or who require limited, conditional use.

---

Populations for whom use is Contraindicated

Galvus must not be used by patients with a known hypersensitivity to the active substance vildagliptin or its excipients. It is also contraindicated for the treatment of Type 1 Diabetes Mellitus ( T1DM) and acute Diabetic Ketoacidosis ( DKA).

Use Not Recommended or Restricted

Age and Development Status

• Pediatric: Use in children and adolescents under 18 years of age is not recommended, as safety and efficacy have not been established.
• Pregnancy/Lactation: Use is not recommended for women who are pregnant or breastfeeding due to insufficient human data.

Condition-Specific Eligibility Rules

• Hepatic Impairment: The medicine is not recommended for patients with clinical evidence of hepatic impairment (including significantly elevated pre-treatment liver enzymes).
• Heart Failure: It is not recommended for patients with New York Heart Association ( NYHA) functional class IV heart failure.
• Renal Impairment: Patients with moderate or severe renal impairment or End Stage Renal Disease ( ESRD) are eligible, but require a specific, restricted daily dose.

Interactions with other medicines and products

The regulatory profile for Galvus (vildagliptin) shows a generally low risk for clinically significant conflicts, defined primarily by specific pharmacodynamic patterns rather than metabolic pathways.

Pharmacodynamic Interaction Risks

Co-administration with certain medicinal products requires regulatory caution due to specific effects:

• Sulfonylureas: Combining vildagliptin with a sulfonylurea results in an additive blood glucose-lowering effect, which officially dictates an increased risk of hypoglycemia. This necessitates a cautionary approach as defined in official prescribing documents.
• ACE-inhibitors: Co-administration with Angiotensin Converting Enzyme (ACE) inhibitors is associated with a reported increased risk of angioedema.

Substances That May Reduce Efficacy

The blood glucose-lowering effect of vildagliptin may be reduced by co-administration with substance classes that increase blood glucose. These include thiazides, corticosteroids, thyroid products, and sympathomimetics.

Metabolic Interaction Potential and Restrictions

Vildagliptin is formally documented as having a low potential for metabolic interaction because it is neither a substrate nor an inhibitor or inducer of the major cytochrome P450 (CYP450) enzymes. This stability minimizes the risk of many drug-drug interactions. Furthermore, studies have shown that while some exposure changes occur with co-administered drugs like Metformin and Valsartan, these effects are officially classified as not clinically relevant and do not require administration restrictions. No medicinal products are listed as formally contraindicated due to interaction risk, and administration is not constrained by food timing.

The mechanism of action of vildagliptin is strictly governed by its role as an indirect modulator of the incretin system, which results in the glucose-dependent modulation of pancreatic hormones.

---

Enzyme Inhibition and Incretin Preservation

Vildagliptin works by selective inhibition of the enzyme Dipeptidyl Peptidase-4 (DPP-4) . This enzyme rapidly breaks down incretin hormones, specifically GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide), which are released from the gut following nutrient ingestion. By blocking DPP-4, the drug prevents the enzymatic inactivation of these hormonal messengers, allowing their active circulating levels to increase and persist longer in the bloodstream. This core mechanism results in the modulation of the physiological response to nutrient absorption.

---

Glucose-Dependent Hormone Modulation

The preserved incretin hormones then travel to the pancreas, influencing the function of both beta-cells (insulin-producing) and alpha-cells (glucagon-producing). This action is fundamentally glucose-dependent: the hormones only enhance insulin secretion and suppress glucagon release when the concentration of glucose in the blood is elevated. This mechanistic design modulates the insulin-to-glucagon ratio, resulting in reduced hepatic glucose production, while avoiding the disruption of the vital glucagon counter-regulatory response needed during low-glucose states. The overall physiological effect is an alteration in the processes of glucose homeostasis, particularly after meals.

The administration of Galvus (vildagliptin) is based on standardized procedures, with modifications specified for certain patient populations.

Official Dosing and Administration

Galvus is an oral tablet taken by mouth. The maximum recommended daily dose of vildagliptin is 100 mg. The administration frequency is determined by the total daily amount prescribed:

Usage Context	Daily Dose and Division	Frequency
Standard Dose (e.g., monotherapy, combination with metformin, TZD, or insulin)	100 mg (administered as 50 mg morning and 50 mg evening)	Two divided doses daily
Lower Dose (with Sulfonylurea)	50 mg	Once daily in the morning

Galvus may be taken with or without meals, as food does not alter the overall absorption of the active substance.

Special Population Instructions

Dosage adjustments are specifically required for patients with impaired kidney function.

• Renal Impairment: For patients with moderate or severe renal impairment, including those on dialysis, the recommended dose is 50 mg once daily. No adjustment is needed for mild renal impairment.
• Hepatic Impairment: Use is not recommended.
• Elderly Patients (ge 65 years): No dose adjustment is required based on age.
• Pediatric Population (< 18 years): Use is not recommended.

Procedural Note

If a dose of Galvus is missed, it should be taken as soon as the patient remembers, but a double dose must not be taken on the same day. Treatment with Galvus is typically part of a continuous, long-term therapeutic regimen.

Galvus: Recent Clinical Evidence

Evidence for Monotherapy: Initial Treatment When Metformin is Not Used

Research has evaluated vildagliptin as a single treatment for adults with Type 2 Diabetes Mellitus (T2DM). This was studied for individuals who cannot tolerate or have medical reasons not to take Metformin, an initial therapy. The evidence comes primarily from Randomized Controlled Trials (RCTs), where researchers monitored changes in Glycosylated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG).

Findings describe patterns observed in these blood sugar measurements over the study period. Additionally, research describes patterns observed in body weight measurements. What remains uncertain is the full picture of the maintenance of blood sugar measurements beyond the typical one-to-two-year study period when used as a single agent.

---

Evidence for Use as an Add-on to Other Oral Diabetes Medications

Galvus was studied for its use in combination with other common oral diabetes medications when a single drug was associated with inadequate blood sugar control. The bulk of the evidence comes from numerous RCTs exploring dual therapy (e.g., with Metformin) and triple oral therapy regimens.

The studies explored changes in HbA1c, FPG, and Postprandial Glucose (PPG) (blood sugar after meals). A significant long-term study explored vildagliptin initiated early in combination with Metformin, tracking patient outcomes for up to five years. For many combinations, follow-up durations were limited for other specific dual or triple oral regimens.

---

Evidence for Use in Combination with Insulin Therapy

Studies explored vildagliptin when used alongside an existing treatment plan that includes insulin. This typically involves adults with T2DM whose blood sugar was associated with inadequate control.

Primary outcomes examined included changes in HbA1c and Mean Blood Glucose (MBG). Findings describe patterns observed where blood sugar measurements were reported to change when vildagliptin was added to the insulin regimen. The majority of follow-up durations were limited in these studies, focusing primarily on short-term changes over 12 to 24 weeks.

---

Main Evidence Gaps and Areas for Further Research

Comparative evidence is lacking to definitively show how vildagliptin compares to all the newest classes of oral antidiabetic agents in large, head-to-head trials over many years. Furthermore, studies have not been established for Galvus in children and adolescents (under 18), indicating limited data for this specific group.

Key Studies & References Vildagliptin (Oral Route) - Drug Information

The official regulatory requirements govern the storage and disposal of Galvus tablets to maintain product stability and ensure environmental safety.

Labeled Storage Temperature:	Not above 30 C (86F).
Protection Requirements:	Store in the original package to protect from moisture.
Child-Safety Storage:	Keep this medicine out of the sight and reach of children.
Disposal Requirement:	Do not throw away via wastewater or household waste; consult a pharmacist.

Official labels mandate that the product must remain in its original container and not be used after the expiry date. Disposal must adhere to specific pharmaceutical waste procedures, which prohibit flushing or placing the tablets in the trash, requiring that a pharmacist be consulted for safe discarding measures.